within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01X_OtherAntineoplasticAgents.L01XK52_NiraparibAndAbiraterone;
model NiraparibAndAbiraterone 
   extends Pharmacolibrary.Drugs.ATC.L.L01XK52;

  annotation(Documentation(
    info ="<html><body><p>This is a fixed-dose combination medication containing niraparib, a PARP inhibitor used primarily in ovarian cancer, and abiraterone acetate, a selective CYP17 inhibitor used in the treatment of metastatic castration-resistant prostate cancer. The combination is intended for treatment of adult patients with certain types of prostate cancer and was approved by the European Union in May 2023.</p><h4>Pharmacokinetics</h4><p>No published literature with population or compartmental pharmacokinetic models for the fixed-dose combination of niraparib and abiraterone (L01XK52) is currently available as of June 2024. Parameter estimates were inferred based on the pharmacokinetic characteristics of individual components and regulatory approval documentation.</p><h4>References</h4><ol></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end NiraparibAndAbiraterone;
